Submitted for Publication: October 18, 2012; final revision received February 10, 2013; accepted February 12, 2013.
Published Online: September 4, 2013. doi:10.1001/jamapsychiatry.2013.1976.
Acquisition of data: Goodby, Dean, Ooi, Nathan, Jones.
Analysis and interpretation of data: Fornito, Harrison, Nathan, Lennox, Suckling, Bullmore.
Drafting of the manuscript: Fornito, Ooi, Nathan, Lennox, Bullmore.
Critical revision of the manuscript for important intellectual content: Fornito, Harrison, Goodby, Dean, Nathan, Lennox, Jones, Suckling, Bullmore.
Statistical analysis: Fornito, Harrison, Bullmore.
Obtained funding: Nathan, Lennox, Jones, Bullmore.
Administrative, technical, or material support: Goodby, Dean, Ooi, Suckling, Bullmore.
Study supervision: Nathan, Lennox, Bullmore.
Conflict of Interest Disclosures: Recruitment, data collection, other direct research costs, and part of Dr Ooi’s salary were funded through a grant provided by GlaxoSmithKline (GSK) to the University of Cambridge (principal investigator, Dr Jones). The research was commissioned to understand neurobiological processes related to risk for psychosis and GSK was contracted with the University of Cambridge to support unrestricted publication of research findings. GlaxoSmithKline has no commercial or proprietary interest in this study. Dr Nathan was employed full-time by GSK. Dr Bullmore is employed half-time by GSK and holds stock in GSK. Neither Dr Nathan nor Dr Bullmore received any financial benefits from involvement in this study.
Funding/Support: Dr Fornito’s work was supported by a University of Melbourne CR Roper Fellowship and National Health and Medical Research Council grant 1050504. Dr Harrison’s work was supported by National Health and Medical Research Council Fellowship 628509.